{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:28:06Z","timestamp":1790882886733,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunotherapy targeting immune checkpoint molecules has provided remarkable clinical benefits in cancer patients but no clinically relevant biomarker for predicting treatment outcomes exists. Recently, we demonstrated that glycan structures of serum \u03b1<jats:sub>1<\/jats:sub>-acid glycoprotein (AGP) changed dramatically in cancer patients and that \u03b11,3fucosylated AGP (fAGP) levels increased along with disease progression and decreased responding to chemotherapy treatments. Here, the fAGP was analyzed in sera prospectively obtained from 39 patients with advanced lung cancer who underwent immunotherapy with anti-PD-1 antibody, nivolumab. Twenty-three patients had significantly high fAGP levels above the cut-off value (H-fAGP) at one month after starting the treatment and 20 patients in this group, whose tumor sizes did not decrease, maintained high fAGP levels continuously and subsequently died. However, the other 16 patients, whose fAGP levels decreased or maintained below the cut-off value (L-fAGP), survived during a 2-year observation even though 5 patients in this group had no tumor shrinkage. Accordingly, the overall survival rate was found to significantly correlate with the fAGP level. Multivariate analyses revealed that the H-fAGP was an independent risk factor for cancer progression. Therefore, the fAGP level appeared to be a reliable biomarker for predicting clinical efficacy of immunotherapy with nivolumab.<\/jats:p>","DOI":"10.1038\/s41598-019-51021-2","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T10:32:32Z","timestamp":1570703552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Fucosylated \u03b11-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Takehiko","family":"Yokobori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Asao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Mogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"51021_CR1","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734\u20131736 (1996).","journal-title":"Science"},{"key":"51021_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki, T. & Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19, 813\u2013824 (2007).","journal-title":"Int. Immunol."},{"key":"51021_CR3","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99, 12293\u201312297 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51021_CR4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"51021_CR5","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"51021_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","volume":"24","author":"Y Iwai","year":"2017","unstructured":"Iwai, Y. et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci. 24, 26\u201337 (2017).","journal-title":"J. Biomed. Sci."},{"key":"51021_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"51021_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11864-017-0476-y","volume":"18","author":"C Ramamurthy","year":"2017","unstructured":"Ramamurthy, C., Godwin, J. L. & Borghaei, H. Immune checkpoint inhibitor therapy: what line of therapy and how to choose? Curr. Treat. Options in Oncol. 18, 33 (2017).","journal-title":"Curr. Treat. Options in Oncol."},{"key":"51021_CR9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480\u2013489 (2011).","journal-title":"Nature"},{"key":"51021_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","volume":"55","author":"AT Hryniewicki","year":"2018","unstructured":"Hryniewicki, A. T. et al. Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians. J. Emerg. Med. 55, 489\u2013502 (2018).","journal-title":"J. Emerg. Med."},{"key":"51021_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00270","volume":"8","author":"S Kitano","year":"2018","unstructured":"Kitano, S., Nakayama, T. & Yamashita, M. Biomarkers for immune checkpoint inhibitors in melanoma. Front Oncol. 8, 1\u20138 (2018).","journal-title":"Front Oncol."},{"key":"51021_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/PPO.0000000000000185","volume":"22","author":"P Sharma","year":"2016","unstructured":"Sharma, P. Immune checkpoint therapy and the search for predictive biomarkers. Cancer J. 22, 68\u201372 (2016).","journal-title":"Cancer J."},{"key":"51021_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2018.05.005","volume":"52","author":"D Atanackovic","year":"2018","unstructured":"Atanackovic, D. & Luetkens, T. Biomarkers for checkpoint inhibition in hematologic malignancies. Semin. Cancer Biol. 52, 198\u2013206 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"51021_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem, S. et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer 114, 256\u2013261 (2016).","journal-title":"Br. J. Cancer"},{"key":"51021_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ejca.2017.09.004","volume":"86","author":"Y Iijima","year":"2017","unstructured":"Iijima, Y. et al. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. Eur. J. Cancer 86, 349\u2013357 (2017).","journal-title":"Eur. J. Cancer"},{"key":"51021_CR16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/cas.13226","volume":"108","author":"N Yamazaki","year":"2017","unstructured":"Yamazaki, N. et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Sci. 108, 1022\u20131031 (2017).","journal-title":"Cancer Sci."},{"key":"51021_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF00731324","volume":"12","author":"W van Dijk","year":"1995","unstructured":"van Dijk, W., Havenaar, E. C. & Brinkman-van der Linden, E. C. M. \u03b11-Acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. Glycoconjugate J. 12, 227\u2013233 (1995).","journal-title":"Glycoconjugate J."},{"key":"51021_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0167-4838(00)00153-9","volume":"1482","author":"T Foumier","year":"2000","unstructured":"Foumier, T., Medjoubi-N, N. & Porquet, D. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta 1482, 157\u2013171 (2000).","journal-title":"Biochim. Biophys. Acta"},{"key":"51021_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0009-8981(84)90352-8","volume":"138","author":"JE Hansen","year":"1984","unstructured":"Hansen, J. E., Larsen, V. A. & B\u00f8g-Hansen, T. C. The microheterogeneity of alpha 1-acid glycoprotein in inflammatory lung disease, cancer of the lung and normal health. Clin. Chim. Acta 138, 41\u201347 (1984).","journal-title":"Clin. Chim. Acta"},{"key":"51021_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF00731326","volume":"12","author":"A Mackiewicz","year":"1995","unstructured":"Mackiewicz, A. & Mackiewicz, K. Glycoforms of serum \u03b11-acid glycoprotein as markers of inflammation and cancer. Glycoconjugate J. 12, 241\u2013247 (1995).","journal-title":"Glycoconjugate J."},{"key":"51021_CR21","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1002\/cncr.20713","volume":"101","author":"S Hashimoto","year":"2004","unstructured":"Hashimoto, S. et al. \u03b11-Acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 101, 2825\u20132836 (2004).","journal-title":"Cancer"},{"key":"51021_CR22","doi-asserted-by":"crossref","first-page":"12662","DOI":"10.1016\/S0021-9258(18)99927-8","volume":"269","author":"R Mollicone","year":"1994","unstructured":"Mollicone, R. et al. Molecular basis for plasma \u03b1(1,3)-fucosyltransferase gene deficiency (FUT6). J. Biol. Chem. 269, 12662\u201312671 (1994).","journal-title":"J. Biol. Chem."},{"key":"51021_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000019104","volume":"16","author":"S Yazawa","year":"1999","unstructured":"Yazawa, S. et al. Plasma \u03b11,3-fucosyltransferase deficiency in schizophrenia. Exp. Clin. Immunogenet. 16, 125\u2013130 (1999).","journal-title":"Exp. Clin. Immunogenet."},{"key":"51021_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000049082","volume":"18","author":"S Tanaka","year":"2001","unstructured":"Tanaka, S. et al. Molecular analysis of plasma \u03b11,3-fucosyltransferase deficiency and development of the methods for its genotyping. Exp. Clin. Immunogenet. 18, 1\u201312 (2001).","journal-title":"Exp. Clin. Immunogenet."},{"key":"51021_CR25","doi-asserted-by":"publisher","first-page":"834790","DOI":"10.1155\/2013\/834790","volume":"10","author":"T Asao","year":"2013","unstructured":"Asao, T. et al. Development of a novel system for mass spectrometric analysis of cancer-associated fucosylation in plasma \u03b11-acid glycoprotein. BioMed. Res. Int. 10, 834790, http:\/\/dx.doi.org\/10.1155\/2013\/834790\u00a0(2013).","journal-title":"BioMed. Res. Int."},{"key":"51021_CR26","doi-asserted-by":"publisher","first-page":"e0156277","DOI":"10.1371\/journal.pone.0156277","volume":"11","author":"S Yazawa","year":"2016","unstructured":"Yazawa, S. et al. Fucosylated glycans in \u03b11-acid glycoprotein for monitoring treatment outcomes and prognosis of cancer patients. PLoS ONE 11, e0156277 (2016).","journal-title":"PLoS ONE"},{"key":"51021_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cca.2017.12.030","volume":"478","author":"S Yazawa","year":"2018","unstructured":"Yazawa, S. et al. A new enzyme immunoassay for the determination of highly sialylated and fucosylated human \u03b11-acid glycoprotein as a biomarker of tumorigenesis. Clin. Chim. Acta 478, 120\u2013128 (2018).","journal-title":"Clin. Chim. Acta"},{"issue":"Suppl_1","key":"51021_CR28","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"R. L. Wahl","year":"2009","unstructured":"Wahl, R. L. et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122S\u2013150S (2009).","journal-title":"Journal of Nuclear Medicine"},{"key":"51021_CR29","doi-asserted-by":"publisher","first-page":"76:10.1186","DOI":"10.1186\/s40425-016-0178-1","volume":"4","author":"GV Masucci","year":"2016","unstructured":"Masucci, G. V. et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J. Immunother. Cancer 4, 76:10.1186 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"51021_CR30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558\u2013562 (2014).","journal-title":"Nature"},{"key":"51021_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"51021_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.critrevonc.2016.03.007","volume":"101","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman, O. Correlation between PD-L1 expression and outcome of NSCLC patients with anti-PD-1\/PD-L1 agents: A meta \u2013 analysis. Crit. Rev. Oncol. Hemat. 101, 75\u201385 (2016).","journal-title":"Crit. Rev. Oncol. Hemat."},{"key":"51021_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"51021_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4052\/tigg.10.235","volume":"10","author":"W van Dijk","year":"1998","unstructured":"van Dijk, W., Brinkman-van der Linden, E. C. M. & Havenaar, E. C. Glycosylation of \u03b11-acid glycoprotein (orosomucoid) in health and disease: occurrence, regulation and possible functional implications. Trends in Glycosci. Glycotechnol. 10, 235\u2013245 (1998).","journal-title":"Trends in Glycosci. Glycotechnol."},{"key":"51021_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bbagen.2005.03.012","volume":"1725","author":"K Higai","year":"2005","unstructured":"Higai, K. et al. Glycosylation of site-specific glycans of \u03b11-acid glycoprotein and alterations in acute and chronic inflammation. Biochim. Biophys. Acta 1725, 128\u2013135 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"51021_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7124\/bc.00015E","volume":"26","author":"NI Stekleneva","year":"2010","unstructured":"Stekleneva, N. I. et al. Expression and structural-functional alterations of \u03b1-1-acid glycoprotein at the pathological state. Biopolym. Cell 26, 265\u2013272 (2010).","journal-title":"Biopolym. Cell"},{"key":"51021_CR37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/glycob\/6.4.407","volume":"6","author":"CM Brinkman-van der Linden","year":"1996","unstructured":"Brinkman-van der Linden, C. M. et al. Oral estrogen treatment induces a decrease in expression of sialyl Lewis x on \u03b11-acid glycoprotein in females and male-to-female transsexuals. Glycobiology\u00a0\n                           6, 407\u2013412 (1996).","journal-title":"Glycobiology"},{"key":"51021_CR38","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s10067-007-0572-7","volume":"26","author":"A Olewicz-Gawlik","year":"2007","unstructured":"Olewicz-Gawlik, A. et al. Fucosylation of serum \u03b11-acid glycoprotein in rheumatoid arthritis patients treated with infliximab. Clin. Rheumatol. 26, 1679\u20131684 (2007).","journal-title":"Clin. Rheumatol."},{"key":"51021_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","volume":"45","author":"K Kaira","year":"2018","unstructured":"Kaira, K. et al. Metabolic activity by 18F-FDG-PET\/CT is predicted of early response after nivolumab in previously treated NSCLC. Eur. J. Nucl. Med. Imaging\u00a045, 56\u201366 (2018).","journal-title":"Eur. J. Nucl. Med. Imaging"},{"key":"51021_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0304-4076(81)90071-3","volume":"16","author":"H Akaike","year":"1981","unstructured":"Akaike, H. Likelihood of a novel and informative criteria. J. Econom. 16, 3\u201314 (1981).","journal-title":"J. Econom."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51021-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:28:04Z","timestamp":1671287284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51021-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51021"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51021-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"13 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14503"}}